Completed Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma NCT01542918 Conditions Disease Attributes, Eye Neoplasms, Hemic and Lymphatic Diseases, +13 more Locations University of California, San Francisco — San Francisco, California, United States View Trial Details
